Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 15/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653571 | 0.83 | AURKA (0.70) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL13055172 | 0.75 | RET (0.40) | AURKAAURKBSRCGSK3B | |
| SCHEMBL14423530 | 0.71 | AURKA (0.49) | AURKAAURKBSRCGSK3B | |
| SCHEMBL12430982 | 0.71 | AURKB (0.70) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL13081792 | 0.70 | AURKB (0.66) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL786478 | 0.70 | AURKA (0.52) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL5070928 | 0.70 | AURKB (0.64) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL12430993 | 0.70 | AURKB (0.69) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL5069306 | 0.69 | AURKB (0.63) | AURKAAURKBSRCGSK3BAURKC | |
| SCHEMBL801629 | 0.69 | ITK (0.57) | AURKAAURKBSRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | AURKA 10/4885AURKB 18/4885SRC 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.